Member Info for Jarv55

Oleeiner is buying lol

Dave you are quite right what you say and Olener won't make any difference to the price you keep chatting between yourselves in the mean time someone is quietly accumulating the free float and when news does land this will rise very quickly because your trades or my trades are not going to make much difference if that is going into sticky hands. I think we will see a break in price by the end of the week we will see.

Dave there are new investors coming in so I think it is relevant. God help you if I actually do start researching this properly. Its a tech trade for me at the moment but I do like what I see. Have to have a bit of balance. I agree with your taking 30% comments but I find it very odd that you declare your every trade on a bb. Also find it odd that there are a few muppets here as well Oleeiner being one of them.

Dave its not spamming its getting research on this bb have you got any or are just trading the techs?

https://twitter.com/search?q=biotrinity&src=typd

https://www.biotrinity.com/

Friday - Physiomics back in the UK office after their AACR Chicago trip Monday - start of BioTrinity Tuesday - Company Update at BioTrinity Wednesday - Innovate UK hold their event at BioTrinity on Investing �0.5-1.5m into SMEs involved in Precision Medicine projects (having already awarded Physiomics several contracts for Precision Medicine studies in association with Oxford Uni and Oxford NHS)

The Stigologist 20 Apr '18 - 12:31 - 2465 of 2468 0 0 0 Should be a great few days coming up for PYC at BioTrinity Note one of the first sessions is on "AI and Drug Discovery" htTps://www.biotrinity.com/sites/default/files/BTR18%20-%20Agenda%2004.04%20v2_0.pdf

htTps://healthitanalytics.com/news/cancer-detection-company-gets-900m-from-pharma-vc-investors "GRAIL, Inc., a precision medicine and life sciences company aiming to develop new very early detection techniques for cancer, has attracted more than $900 million in investment capital from some of the most well-known names in pharmaceutical sales and development. Bristol-Myers Squibb, Celgene, Merck, and Johnson & Johnson Innovations have joined with other strategic investors, including Amazon�s Jeff Bezos and McKesson Ventures, to contribute hundreds of millions to the company�s financial future. �We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,� said Jeff Huber, GRAIL�s Chief Executive Officer. �I believe that GRAIL�s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art computer science and data science is unparalleled in the field of cancer detection."

"This grant project, focused on the personalisation of oesophageal cancer treatment, has driven insights that may be integrated into our core Virtual Tumour offering and will also be the subject of thought capital that will be exploited over the course of this calendar year at industry conferences and through the publication of scientific papers in order to garner further interest from the drug research community. Finally, the ideas generated by this project have the potential to be taken forward in a further personalised medicine project for which the Company is currently seeking funding." Having presented 'successfully' last week at the AACR conference in Chicago,US, this coming week they will present on Tuesday 24th April 2018 at BioTrinity in the UK (Europe's leading Investment and Partnering conference for the BioPharma industry). Following that their previous funding partners the Government Innovate UK body will be launching a Personalised Medicine investment accelerator looking to invest �0.5m-1.5m in projects run by SMEs. hTtps://www.eventbrite.co.uk/e/leveraging-publicprivate-investment-tickets-44180316516 Now clearly a �3m company like Physiomics winning a big funding contract like that would be both an immense validation of their technology and approach but also fund their in a NON-DILUTIVE manner for many years. It's interesting that the UK Government is funding SMEs to tackle the Holy Grail of Personalised Medicine but there are other massive AI companies involved who could I suggest partner with Physiomics. Imagine �3m Physiomics announcing a deal with Jeff Bezos' $1bn+ cancer detection/personalised medicine start-up/roll-up Grail or how about with Google's UK AI specialist DeepMind (which they bought for $500m) and has an operation called DeepMind Health looking to work with Academics and the NHS for cancer detection/personalised medicine. This is something the market has not considered as of yet because they still see PYC as simply being a Company that will have biotechs and Pharmas as potential customers. htTps://theconversation.com/deepmind-can-we-ever-trust-a-machine-to-diagnose-cancer-88707

interesting posts on Advfn from Stig 19 Apr '18 - 19:08 - 2461 of 2468 0 1 0 Now get a load of this. Start researching DeepMind Health and GRAIL before next week ! ------------------------------------------------------------------------------------ PYC Physiomics (Share Price 6p ; Shares o/s 58m ; Mkt Cap �3.5m) On November 30th 2017 the ex-Founder of Physiomics made the following points in a long post in which he also claimed he believed PYC should be worth over 100p+ *Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced * PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. htTp://uk.advfn.com/cmn/fbb/thread.php3?id=31109702&from=3710 Since then the Physiomics management have on a number of occasions talked about Personalised Medicine, Cloud technology, AI (Artificial Intelligence) e.g. Interim Results February 2018 hTtps://www.investegate.co.uk/physiomics-plc--pyc-/rns/interim-results-statement/201802190700021669F/ "We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process."

Eye 22 give me a dm on twitter

Think anyone selling now is nuts myself but there you go each to their own

Webcast available https://www.c4xdiscovery.com/investors/financials-and-company-documents.html

started a twitter dm group for research if any of you want to join follow me @Jarvy55 and dm me

https://twitter.com/Jarvy55/status/986230956066516993

Added a few more

leslieby follow me at @Jarvy55 dm me and I will add you in

The Stigologist 16 Apr '18 - 18:51 - 2379 of 2388 0 2 0 Whilst quite rightly next week's Conference presentation and 'Company Update' has excited the share price today I think it's worth pointing out Physiomics are still at the ongoing AACR #AACR #AACR18 Conference in the United States where they are presenting their 'Late Breaking Abstract' on their Personalised Cancer Care Decision Support System tool. ( htTps://www.investegate.co.uk/physiomics-plc--pyc-/rns/physiomics-to-present-at-aacr-annual-meeting/201804040700046692J/ ) Think it's worth drawing peoples attention to what you need to show the experts at AACR that your Abstract is worthy of presentation and publication at their conference. From the AACR website :- htTp://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=136&DetailItemID=708#.WtTgbejwa00 Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline may be submitted for consideration as a late-breaking abstract. Only those abstracts that are deemed to be of high scientific priority will be accepted. Now why would the Conference organisers deem Physiomics abstract to meet the above requirements ? Which of the 'great and good' who attend AACR will now be beating a path to Physiomics door to partner and further develop their technology ? Let's just say it might not just be multi-billion Pharmaceutical companies wanting to partner with PYC

Nice to see a directors buy http://www.lse.co.uk/share-regulatory-news.asp?shareprice=C4XD&ArticleCode=qcbypeb7&ArticleHeadline=DirectorPDMR_Shareholding